Study on the Influence of Low-dose Mifepristone in Uterine Endometrium

Objective To study on the influence of low-dose mifepristone in uterine endometrium.Methods Forty women with uterine leiomyomata or adenomyosis,were chosen at random as the control group in this study.All took mifepristone 12.5 mg daily for one month from the fifth day of menstruation cycle,and then took it 6.25mg daily for 3 months.Two menstruation cycles were monitored.First,follicular phase before treating(from the first day to the ninth day of menstruation cycle).Second,from the 120th day of taking medicine to a week after treating.Every time,uterine endometrial thickness were measured by transvaginal ultrasonography.And the serum glutamic-pyruvic transaminase level,creatinine level were measured in the situation of forbiding food.The Proliferating Cell Nuclear Antigen Index were measured by immunohistochemistry.So did the pathological examination of endometrial specimens,the serum E2 levels and FSH levels.Everyday the patients kept diary,recording the vagina bleeds,discomfort symptom and etc.Appling SPSS11.5 statistics software to carry on datas.Results ①E2 level before treating is placed in the follicular phase of the cycle(69.73±41.58pg/mL).However,E2 level treated with mifepristone descends obviously(P 0.01),being placed in the postmenopausal phase(35.88±10.98 pg/mL).②FSH level has no obvious differenc e(P 0.05)between treated with mifepristone(5.88±1.73IU/L)and untreated with it(5.02±2.91IU/L).③The pathological examination shows endometrial conversion rate is 33.3%,and detect endometrial hyperplasia,but no atypical hyperplasia was noted.PCNA index has no obvious difference between treated with mifepristone(820.60±48.05)and untreated with mifepristone(795.80± 59.70)(P 0.05).④GPT and Cr levels were unaffected after mifepristone administration(P 0.05).Conclusions Low-dose mifepristone can not inhibit endometrium because of its slender estrogen effection.After taking it for 4 month,there is a endometrial hyperplasia phenomenon but no atypical hyperplasia,so this way of taking it is safe,but Further investigation of the endometrial effects of mifepristone must be conducted if mifepristone is to be used for longer than 4 months.